Access
To read this story in full you will need to login or make a payment (see right).
Authors
Nature 452, x (17 April 2008) | doi:10.1038/7189xa; Published online 16 April 2008
nature jobs
Faculty Position - Sustainability at the Water-Energy Nexus
- University of Michigan
- Ann Arbor, MI
Associate Scientist, Compound Screening
- Philip Morris International (PMI)
- Neuchatel, Switzerland
Making the paper: Sakari Kauppinen
It is only a few years since tiny RNA molecules called microRNAs were found to have roles in disease, but a therapeutic approach that targets one of them is already yielding promising results. Sakari Kauppinen and his colleagues at Santaris Pharma in Hørsholm, Denmark, in collaboration with the Connecticut-based company RxGen and Stanford University in California, have successfully blocked the activity of one type of microRNA in non-human primates.
To read this story in full you will need to login or make a payment (see right).